Getting to Know PharmaTimes Clinical Research of the Year Nominee Matthew Jeffery

By Kayt Leonard

Public Relations Specialist

The PharmaTimes International Clinical Researcher of the Year award is one of the most recognized awards in the clinical research industry. And one of the toughest to earn, too.

PharmaTimes is known for the rigorous review process, detailed application criteria, and highly selective qualification factors chosen by a dedicated, skilled steering committee led by industry experts. And this year, PSI CRO’s own Matthew Jeffery is among the finalists for this award.

Before the awards announcement on May 17th, we decided to catch up with Matthew and learn more about the work he does at PSI. We also dug into his thoughts on the International Award, and what the future looks like for this promising Clinical Trials Associate.

Why did you choose to pursue clinical research?

I have always been interested in working in clinical research.  I studied Psychology at both the undergraduate and postgraduate level for four years, and I became interested in researching mental health and psychology. By working at PSI, I have been exposed to other areas of clinical research such as the Crohn’s, Haemophilia, and Bacterial Infection programs I’ve worked on. My interests in the field of clinical research have certainly broadened past mental health and I’m excited to join other therapeutic area study projects to continue researching and learning.

Tell us about your experience so far as a CTA:

I started as a CTA at PSI at the end of October 2017. Once I completed my training in January of 2018, I started working on studies in Haemophilia, Crohn’s Disease, and Bacterial Infection.

What about the CTA role resonates with you?

As a CTA, my role is part of a process that may ultimately have a positive impact on a person. This motivates me to carry out my duties to the best of my ability every single day. It’s important to me to go the extra mile for every project and make sure you’re doing the absolute most for every study. As much as I focus on that aspect, I relish the exposure to many different professionals in the field. Whether this be with individuals from the study team, participating sites or the sponsor, the CTA role gives me the experience of communicating with a variety of different individuals all over the globe. I’m able to learn a great deal about the industry and build an incredible network of research professionals at the same time.

What are your clinical research career goals?

I want to go as far as possible in the clinical research industry and learn as much as possible about its processes. Ultimately, I’d like to have a more hands-on approach to clinical trial conduct. My next step in clinical research will likely be pursuing a career as a CRA.

What does it mean to you to be recognized by PharmaTimes?

Being recognised by PharmaTimes is an absolute privilege. To be nominated in the first place by the judges from the steering group is an honour. This is not only a reflection of my own performance but also my colleagues. They have made me feel at home at my organisation and really work as a team to provide the best results for our projects. As all CTA’S know, our work is vital for clinical trials to run smoothly. And when they do, trials have the ability to change lives. I see my career in clinical trials and being recognised by PharmaTimes as a milestone in achieving my goals in this industry.

From all of us at PSI, we’re wishing Matthew the best of luck at the PharmaTimes International Award Ceremony on May 17th. We’re so proud of the work that our employees do every single day. Join us in congratulating Matthew on this well-earned recognition as a finalist!